RE:RE:RE:RE:RE:Financials The most important part is that Calyx is already profitable:
Sales revenue of $1,674,269 and cost of goods sold of $1,346,722 recognized for the three months ended April 30, 2018, were exclusively derived from Calyx Brands Inc., which was acquired on March 15, 2018. The gross profit from March 15th to April 30th, 2018 was $327,547 or 19.6%.
Give it more time and see how we start increasing gross profits and lowering our overall losses.
Also, part of the net loss was incurred by 1 time costs such as:
- Acquisition and project evaluation costs of $185,300 (2017 - $Nil) are mostly related to transaction costs associated to the acquisition of Calyx Brands Inc.
- Increase of $465,643 in office and general compared to comparative period is mainly due to the first-time inclusion of Calyx’s office and general expense of $413,508 for the period after acquisition. Included in the office and general was $146,399 of one-time bad debt expense.
Who knows if there will be a selloff from these financials, but nobody can argue against the fact that NH has now accomplished a huge milestone that can turn the company around.
Add all the perks of the 75% acquisition of Green Therapeutics in the ever growing market of Nevada and I think Posner's estimation for overall profitability in 2019 doesn't seem so out of reach afterall!
Damasta wrote: I don't see much upside but lets wait and see what the market thinks.
total assets up 136.5%
total liabilities up 445%
total shareholder equity up 30.5%
shares outstanding up 17.4%
Total equity $1,844,871 = .00646 cents per share
Shares o/s = 285,290,684 according to stockwatch